TAK-733

N/A

Report date: 2026/02/07 20:00:33
NME

Base Information

Drug NameTAK-733
Drug Alias NameREC-4881TAK-733
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsSolid tumoursAdenomatous Polyposis ColiMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRecursion Pharmaceuticals Inc
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsAdenomatous Polyposis Coli
Inactive IndicationsSolid tumoursMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A